{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:53:59Z","timestamp":1789588439309,"version":"build-2803163510"},"reference-count":85,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by both an abnormal expansion of the granuloblastic clone and the pathognomonic presence of the Philadelphia (Ph) chromosome that generates the BCR::ABL1 oncoprotein. Despite the surfacing of tyrosine kinase Inhibitors (TKIs) in 2001, which changed the evolution of the disease, resistance due to point mutation or compound alteration during treatment with target therapy may occur. One of the mutations that is still an on-going challenge in clinical and scientific field is the T315I mutation, since it gives patients a poor prognosis attributable to acquired resistance to therapy. In the following narrative review, we will discuss the current knowledge on the T315I mutation, explore the most suitable treatment options, examine the role of third-generation tyrosine kinase inhibitors, and outline potential future therapeutic strategies.<\/jats:p>","DOI":"10.3390\/ijms262311285","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:28:07Z","timestamp":1763746087000},"page":"11285","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation"],"prefix":"10.3390","volume":"26","author":[{"given":"Federico","family":"Pierro","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Stella","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8804-2640","authenticated-orcid":false,"given":"Manlio","family":"Fazio","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Russo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5896-8573","authenticated-orcid":false,"given":"Michele","family":"Massimino","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mirabile","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Belletti","sequence":"additional","affiliation":[{"name":"IRCCS Bonino Pulejo Center, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":false,"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-158X","authenticated-orcid":false,"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101552","DOI":"10.1016\/j.beha.2024.101552","article-title":"Cytogenetics and genomics in CML and other myeloproliferative neoplasms","volume":"37","author":"Kreipe","year":"2024","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Minciacchi, V.R., Kumar, R., and Krause, D.S. (2021). Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. Cells, 10.","DOI":"10.3390\/cells10010117"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: Mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of bcr-abl in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","article-title":"Acute lymphocytic leukaemia","volume":"406","author":"Kantarjian","year":"2025","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000492941","article-title":"Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph\u2019+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report","volume":"63","author":"Pirosa","year":"2018","journal-title":"Chemotherapy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29906","DOI":"10.18632\/oncotarget.15369","article-title":"Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy","volume":"8","author":"Luatti","year":"2017","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0950-3536(97)80003-0","article-title":"BCR-ABL gene variants","volume":"10","author":"Melo","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.21873\/invivo.11802","article-title":"Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells","volume":"34","author":"Massimino","year":"2020","journal-title":"In Vivo"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic Myeloid Leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fonc.2019.01132","article-title":"Management of Chronic Myeloid Leukemia in Advanced Phase","volume":"9","author":"Bonifacio","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.14694\/EdBook_AM.2015.35.e381","article-title":"Diagnosing and Managing Advanced Chronic Myeloid Leukemia","volume":"35","author":"Deininger","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/02841861003660031","article-title":"Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"49","author":"Stagno","year":"2010","journal-title":"Acta Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Stella, S., Zammit, V., Vitale, S.R., Pennisi, M.S., and Massimino, M. (2019). Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092226"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMe068073","article-title":"Circumventing resistance to kinase-inhibitor therapy","volume":"354","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e35953","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Kantarjian","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_24","first-page":"611","article-title":"NCCN guidelines updates: Discontinuing TKI therapy in the treatment of chronic myeloid leukemia","volume":"17","author":"Shah","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood.2024024657","article-title":"Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: Results from the ASCEND study","volume":"144","author":"Yeung","year":"2024","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2019","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): A single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial","volume":"36","author":"Cortes","year":"2022","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ajh.26852","article-title":"The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors","volume":"98","author":"Jabbour","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"Shakespeare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: Final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1182\/bloodadvances.2025016042","article-title":"Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL","volume":"9","author":"Mauro","year":"2025","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11899-019-00543-7","article-title":"Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors","volume":"14","author":"Yaghmaie","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: A position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"Eide","year":"2007","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.leukres.2007.08.008","article-title":"Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis","volume":"32","author":"Stagno","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/164_2017_81","article-title":"Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia","volume":"Volume 249","author":"Romano","year":"2018","journal-title":"Mechanisms of Drug Resistance in Cancer Therapy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/15384047.2017.1294289","article-title":"Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression","volume":"18","author":"Akram","year":"2017","journal-title":"Cancer Biol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.ccell.2024.08.004","article-title":"Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy","volume":"42","author":"Eide","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation","volume":"97","author":"Liu","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jcb.26257","article-title":"Pathological role of a point mutation (T315I) in BCR-ABL1 protein\u2014A computational insight","volume":"119","author":"Rajendran","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1179\/1607845412Y.0000000050","article-title":"Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance","volume":"18","author":"Chahardouli","year":"2013","journal-title":"Hematology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.31557\/APJCP.2018.19.12.3317","article-title":"Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia","volume":"19","author":"Othman","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2016.145888","article-title":"Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia","volume":"101","author":"Baer","year":"2016","journal-title":"Haematologica"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.bbrc.2018.07.127","article-title":"Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy","volume":"503","author":"Sandt","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/ajh.27037","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era","volume":"98","author":"Haddad","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ajh.26764","article-title":"Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT","volume":"98","author":"Chalandon","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2016.03.012","article-title":"Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia","volume":"22","author":"Xu","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00277-020-03949-z","article-title":"T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes","volume":"99","author":"Ting","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/ajh.26686","article-title":"Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia","volume":"97","author":"Kantarjian","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib","volume":"316","author":"Singh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","article-title":"Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials","volume":"38","author":"Jabbour","year":"2024","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome--positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ebiom.2019.11.004","article-title":"CDK4\/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML","volume":"50","author":"Byrgazov","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2217\/pgs-2016-0049","article-title":"Deep Molecular Response by IFN-\u03b1 and Dasatinib Combination in a Patient with T315I-Mutated Chronic Myeloid Leukemia","volume":"17","author":"Zhou","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_70","first-page":"100184","article-title":"T315I-mutated myeloid sarcoma","volume":"12","author":"Zhang","year":"2019","journal-title":"Leuk. Res. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.5045\/br.2023.2023017","article-title":"Asciminib: The first-in-class allosteric inhibitor of BCR::ABL1 kinase","volume":"58","author":"Choi","year":"2023","journal-title":"Blood Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","article-title":"Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results","volume":"37","author":"Mauro","year":"2023","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of resistance to the BCRABL1 allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41375-024-02327-2","article-title":"Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation","volume":"38","author":"Ernst","year":"2024","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jnci\/djx236","article-title":"Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition","volume":"110","author":"Mitchell","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: Results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.leukres.2018.12.013","article-title":"A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+CML","volume":"78","author":"Gleixner","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_78","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41375-024-02248-0","article-title":"Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations","volume":"38","author":"Curik","year":"2024","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1183052","DOI":"10.3389\/fphar.2023.1183052","article-title":"I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition","volume":"14","author":"Gao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41598-021-04654-1","article-title":"Pterostilbene downregulates BCR\/ABL and induces apoptosis of T315I-mutated BCR\/ABL-positive leukemic cells","volume":"12","author":"Kawakami","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cas.15580","article-title":"Targeting the PTP1B-BCR-ABL1 interaction for the degradation of T315I mutant BCR-ABL1 in chronic myeloid leukemia","volume":"114","author":"Elgehama","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"138305","DOI":"10.1016\/j.ijbiomac.2024.138305","article-title":"Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation","volume":"286","author":"Salizzato","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1021\/jm101251q","article-title":"Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer","volume":"54","author":"Pierre","year":"2011","journal-title":"J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T09:04:16Z","timestamp":1763975056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/23\/11285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":85,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262311285"],"URL":"https:\/\/doi.org\/10.3390\/ijms262311285","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}